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 There are 2 a1-ARs on cardiac myocytes:
a1A and a1B. a1A adrenergic receptors
serve important cardioprotective roles
and do not mediate cardiac hypertrophy.
 Dabuzalgron, an oral a1A-AR agonist
developed for the treatment of urinary
incontinence and tolerated well in Phase 2
clinical trials, protects against
doxorubicin-induced cardiotoxicity
in vivo. Dabuzalgron enhances contractile
function, regulates transcription of genes
related to energy production and mito-
chondrial function, and preserves
myocardial ATP content after
doxorubicin.
 Activation of a1A-ARs on cardiomyocytes
protects against doxorubicin cytotoxicity
and enhances mitochondrial function
in vitro. These cytoprotective effects likely
are mediated by activation of ERK 1/2.
 Future studies will explore whether
dabuzalgron, a well-tolerated oral
a1A-AR agonist, might be repurposed to
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ABBR EV I A T I ON S
AND ACRONYMS
a1-AR = alpha-1 adrenergic
receptor
AKO = alpha-1A adrenergic
receptor knockout
ATP = adenosine triphosphate
BP = blood pressure
DOX = doxorubicin
EC50 = half-maximal effective
concentration
ERK = extracellular signal-
regulated kinase
HF = heart failure
HR = heart rate
IP = intraperitoneal








TBARS = thiobarbituric acid
reactive substances
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reAlpha-1 adrenergic receptors (a1-ARs) play adaptive and protective roles in the heart. Dabuzalgron is an oral
selective a1A-AR agonist that was well tolerated in multiple clinical trials of treatment for urinary incontinence,
but has never been used to treat heart disease in humans or animal models. In this study, the authors
administered dabuzalgron to mice treated with doxorubicin (DOX), a widely used chemotherapeutic agent
with dose-limiting cardiotoxicity that can lead to heart failure (HF). Dabuzalgron protected against DOX-
induced cardiotoxicity, likely by preserving mitochondrial function. These results suggest that activating
cardiac a1A-ARs with dabuzalgron, a well-tolerated oral agent, might represent a novel approach to
treating HF. (J Am Coll Cardiol Basic Trans Science 2017;2:39–53) © 2017 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).E vidence from studies in cells andanimals indicates that alpha-1adrenergic receptors (a1-ARs) play
numerous protective roles in the heart
(reviewed in O’Connell et al. [1]). There are
3 a1-AR subtypes: a1A, a1B, and a1D. In ro-
dent and human myocardium, the a1A and
a1B predominate, and there is no measurable
a1D. The a1D is the major a1-AR subtype in
human and mouse coronary arteries, where
its activation promotes vasoconstriction
(2,3). The role of the myocardial a1B remainsunclear, but multiple lines of evidence suggest that
the cardioprotective effects of nonselective a1-AR ag-
onists are mediated by the a1A. Mice overexpressing
the a1A have increased contractility (4) and are pro-
tected from ischemia-reperfusion injury (5), myocar-
dial infarction (6,7), and transverse aortic
constriction (8). Abrogation of these adaptive pro-
cesses may also account for the 2-fold increase in inci-
dent heart failure (HF) in hypertensive patients
treated with the non-selective a1-AR antagonist, dox-
azosin, in ALLHAT (Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial)
(9). These findings and other evidence from animal
and human studies suggest that activating myocar-
dial a1A-ARs could be therapeutically effective in HF.SEE PAGE 54In this study, we used the oral selective a1A agonist
dabuzalgron (Ro 115-1240) to test our hypothesis that
stimulation of myocardial a1As could confer car-
dioprotection without increasing blood pressuretest they are in compliance with human studies committe
d Food and Drug Administration guidelines, including patien
: Basic to Translational Science author instructions page.
ceived September 13, 2016; revised manuscript received Octob(BP) through vascular a1-AR activation. Roche
developed dabuzalgron for the treatment of urinary
incontinence. It showed excellent a1A selectivity in
preclinical testing (10) andwas well tolerated by a total
of 1,223 women in a Phase 1 trial (11); 2 Phase 2 ran-
domized multicenter trials (Roche NN16378 and
NN16691); and a subsequent open-label study (Roche
NN16586). Importantly, there were no significant
changes in BP in the subjects who received dabuzal-
gron in any of these trials, suggesting that the chosen
dose did not affect vascular tone. When interim anal-
ysis of the Phase 2 trials revealed no clinically mean-
ingful difference in urinary incontinence between the
dabuzalgron and placebo groups, Roche decided to
close trial enrollment and halt further development of
dabuzalgron. The drug never has been used either
clinically or experimentally to treat heart disease.
We chose to test the therapeutic efficacy of dabu-
zalgron in preventing heart injury using an anthra-
cycline cardiotoxicity model, given previous evidence
demonstrating a1A-mediated cytoprotection after
doxorubicin (DOX) treatment (12–14). Anthracyclines,
including DOX, are highly effective and commonly
used chemotherapeutic agents, but have dose-
limiting cardiotoxicity. Although the incidence of
anthracycline-induced cardiomyopathy has declined
with contemporary dosing regimens, left ventricular
dysfunction still occurs in 20% to 30% of anthracy-
cline recipients (15,16) and remains an important
cause of systolic HF. Numerous mechanisms contri-
bute to cardiomyocyte injury after anthracycline
administration, but mitochondrial dysfunction and
broad deficits in cardiomyocyte energy productiones and animal welfare regulations of the authors’
t consent where appropriate. For more information,
er 11, 2016, accepted October 12, 2016.
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41are central to the pathogenesis (reviewed in
Tokarska-Schlattner et al. [17]).
Here, we show that dabuzalgron protects against
the cardiotoxic effects of DOX in vitro and in vivo by
activating the a1A-AR, and we demonstrate that
preservation of mitochondrial function is one novel
mechanism underlying this benefit.
METHODS
Dabuzalgron was synthesized by Angene (Hong Kong)
per published chemical structure (18), and its purity
and identity were confirmed. Mice were 8- to 12-week-
old males: C57Bl6J wild-type (WT) or a1A-AR knockout
(AKO) mice, which were congenic on a C57Bl6J back-
ground. Animal care and experimental protocols were
approved by the University of North Carolina at Chapel
Hill Institutional Animal Care and Use Committee and
complied with “Guide for the Care and the Use of
Laboratory Animals.” Tail cuff BP and heart rate (HR)
were obtained on awake and trained mice by at least
20 repeated measurements. DOX was administered by
single intraperitoneal (IP) injection, and dabuzalgron
was gavaged twice daily. Echocardiograms were per-
formed on awake, loosely restrained mice. The echo-
cardiogram reader was blind to treatment condition.
Mice were sacrificed by cervical dislocation after an
overdose of isoflurane, and heart tissue was immedi-
ately removed, flash frozen, and then processed for
quantitative reverse transcription polymerase chain
reaction (qRT-PCR), RNAseq, adenosine triphosphate
(ATP) assay, and immunoblotting. Fibrosis was
analyzed in 3 Masson Trichrome-stained sections of 4
or 5 hearts from each treatment group using Aperio
ImageScope software (ImageScope 11.1, Leica Bio-
systems, Buffalo Grove, Illinois). RNAseq was per-
formed at the Carolina Center for Genome Sciences
High Throughput Sequencing Facility. Gene-level
differential expression testing was implemented in
the R package DESeq2 (version 3.1, R Foundation for
Statistical Computing, Vienna, Austria).
Neonatal rat ventricular myocytes (NRVMs) were
isolated as previously described (19). Experiments
including immunoblotting, Annexin V-FLUOS (Sigma-
Aldrich, St. Louis, Missouri), and JC-1 staining were
performed after 36 to 96 h in serum-free medium with
insulin, transferrin, and bromodeoxyuridine. Fluo-
rescence was quantified using a plate reader.
All results are presented as mean  SEM. Compar-
isons were made using the Student t test (groups of 2)
or 1-way analysis of variance (groups of 3) with the
Tukey post hoc analysis (GraphPad Prism, version 5.0,
GraphPad Software, La Jolla, California). EC50 for
extracellular signal-regulated kinase (ERK) activationwas calculated using sigmoidal dose-response anal-
ysis (Prism).
Complete experimental details are available in the
Supplemental Methods.
RESULTS
SELECTIVE a1A-AR ACTIVATION WITH DABUZALGRON
DOES NOT AFFECT HR, BP, OR HEART SIZE IN WT MICE.
Given that nonselective a1-AR agonists such as phen-
ylephrine can increase BP and cause cardiomyocyte
hypertrophy, we sought to determine whether the se-
lective a1A agonist, dabuzalgron, would have similar
effects. Untreated mice were trained on the tail cuff
apparatus daily for 5 days. On Days 6 to 10, mice
received dabuzalgron (1 to 100 mg/kg/day) or water by
gavage twice daily for 5 days with daily BP measure-
ments. After 5 days, no difference in HR or BP could be
found when comparing WT mice treated with dabu-
zalgron and vehicle (Figure 1A).
To test the effect of an a1A agonist on cardiac
hypertrophy, we administered dabuzalgron (1 to
100 mg/kg/day) or vehicle by gavage twice daily for
7 days. There was no measurable change in body
weight or heart weight at any dose (Table 1), and no
difference in heart weight indexed to tibia length could
be found when comparing WT mice treated with
dabuzalgron and water (Figure 1B). We used qRT-PCR
to assay traditionally accepted molecular markers
of hypertrophy in the hearts of mice treated with
dabuzalgron. There was no change in the transcript
abundance of atrial natriuretic peptide, beta myosin
heavy chain, or alpha-skeletal actin (Figure 1C).
Collectively, these findings suggest that the chosen
doses of dabuzalgron do not increase vascular tone or
promote cardiac hypertrophy, 2 properties attributed
to nonselective a1-AR activation.
DABUZALGRONPROTECTSAGAINSTDOXCARDIOTOXICITY
BYACTIVATING THE a1A-AR. To test whether therapeutic
activation of the a1A could prevent DOX-induced
cardiac injury, we treated WT mice and mice lacking
the a1A (AKO mice) with DOX 20 mg/kg IP injection
followed by 7 days gavage with either water or dabu-
zalgron 10 mg/kg twice daily (Figure 2A). There was no
difference in baseline heart weight inWTandAKOmice
(Table 2). All animals treated with DOX lost 10% to 15%
of their body weight. Raw heart weight and heart
weight indexed to tibia length were lower in mice
treated with DOX than in vehicle-treated WT and AKO
controls (Table 2). Survival was 78% inWTmice treated
with DOX and 86% (p ¼NS by Fisher exact test) in mice
treated with DOX and gavaged with dabuzalgron.
Survival in 16 AKO mice treated with DOX was 38%
(p¼0.08 vs. DOX-treatedWTmice by Fisher exact test)
FIGURE 1 Dabuzalgron Does Not Affect BP or Cause Myocardial Hypertrophy in Uninjured WT Mice
(A) Blood pressure (BP) and heart rate (HR) were measured noninvasively in male mice for 10 days. All daily values represent the average of at
least 20 cuff inflations. Mice were trained on the apparatus for the first 5 days, during which no drug was administered. On Days 6 to 10, mice
were gavaged with dabuzalgron (100 ng/kg to 100 mg/kg) or water twice daily. (B) Male mice were treated with dabuzalgron 10 mg/kg by
gavage twice daily for 7 days. Heart weight (HW) (in mg) was indexed to tibia length (TL) (in mm). (C) Quantitative reverse transcription
polymerase chain reaction (qRT-PCR) was performed using heart tissue snap frozen at the time of sacrifice. ANP ¼ atrial natriuretic peptide;
d ¼ day; Dabuz ¼ dabuzalgron; MHCb ¼ myosin heavy chain beta; NS ¼ nonsignificant; skAct ¼ skeletal actin; WT ¼ wild-type.
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Vehicle (12) 27.2  1.0 26.9  0.8 17.5  0.2 109  4 0.40  0.01 6.2  0.2
0.2 (3) 25.5  0.3 25.3  0.4 17.3  0.1 106  4 0.42  0.01 6.1  0.3
2 (6) 26.0  0.8 25.9  0.8 17.5  0.1 106  4 0.41  0.02 6.1  0.2
20 (12) 27.9  1.2 27.3  1.1 17.5  0.1 110  4 0.41  0.01 5.9  0.2
200 (7) 28.4  1.8 27.4  1.6 17.6  0.2 113  6 0.41  0.01 6.1  0.3
Values are mean  SEM unless otherwise indicated.
WT ¼ wild-type.
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43and unaffected by dabuzalgron administration
(Table 2).
Previous studies in rodents (20) and humans (21)
have demonstrated that a1-AR activation increases
inotropy in failing heart tissue, though it has minimal
effects on contractility of the uninjured heart.
Conscious echocardiography on Day 7 after DOX
treatment in WT mice revealed a decrease in con-
tractile function that was prevented by administra-
tion of dabuzalgron (Figure 2B, Table 3). Fractional
shortening and left ventricular end-systolic volume
both were preserved in animals that received dabu-
zalgron after DOX (Table 3), though dabuzalgron had
no effect on echocardiographic parameters in unin-
jured mice (data not shown).
There was no difference in baseline contractile
function of WT and AKO mice (Figure 2B). However,
the surviving DOX-treated AKO mice had significantly
lower fractional shortening than DOX-treated WT
mice (p < 0.01) (Figure 2B). This profound reduction
in contractile function was not rescued by dabuzal-
gron (Figure 2B). The burden of fibrosis as detected by
Masson Trichrome increased significantly after DOX
(Figure 2C), but treatment with dabuzalgron mitigated
this increase.
In summary, treatment with dabuzalgron pre-
served contractile function and reduced fibrosis after
DOX administration. AKO mice treated with DOX had
worse survival and more profoundly impaired con-
tractile function than WT mice. Neither parameter
was affected by dabuzalgron in AKOs, indicating that
the beneficial effects of dabuzalgron require the
presence of the a1A.
DABUZALGRON PRESERVES IN VIVO ABUNDANCE
OF MITOCHONDRIAL FUNCTION TRANSCRIPTS,
UP-REGULATES PGC1a, AND RESTORES ATP SYNTHESIS
AFTER TREATMENT WITH DOX. To investigate the
mechanisms behind dabuzalgron’s cardioprotective
effects after DOX, we used RNAseq to analyze heart
tissue from mice treated with DOX with and without
dabuzalgron. An omnibus test of transcript abun-
dance across all groups was performed using DESeq2
with groups encoded as categorical variables. One
hundred one genes were identified as significant by
meeting the q < 0.05 threshold (the set of genes with
a 5% false discovery rate) (Supplemental Table 1).
Gene set analysis was performed based on the uni-
variate statistics calculated from DESeq2
(Supplemental Tables 2 and 3). Marked differences
were identified in numerous pathways related to
mitochondrial function (Figure 3A).
Further analysis of transcripts within these mito-
chondrial pathways revealed that DOX decreased theabundance of complex I (42 genes) and ATP synthase
subunits (17 genes) (Figure 3B). Treatment with
dabuzalgron restored normal expression of these gene
sets and also increased expression of cytochrome c
oxidase subunits (25 genes) after DOX. Treatment with
dabuzalgron in the absence of DOX increased complex
I subunit abundance, but had no significant effect on
cytochrome c or ATP synthase (Figure 3B).
Many of the genes encoding electron transport and
other key mitochondrial proteins are under tran-
scriptional regulation by peroxisome proliferator-
activated receptor gamma coactivator 1-alpha
(PGC1a) (22). We found that DOX decreased PGC1a
abundance in vivo (Figure 3C), consistent with prior
reports (23). Treatment with dabuzalgron increased
PGC1a abundance in the hearts of mice treated with
either DOX or vehicle control (Figure 3C).
To assess the functional effect of these transcrip-
tional differences, we assayed ATP content in freshly
harvested heart homogenates. DOX decreased ATP
content by 23  7% compared to untreated hearts,
consistent with previous reports (17) (Figure 3D).
Treatment with dabuzalgron restored ATP content in
the hearts of DOX-treated mice, but did not affect ATP
in uninjured mice. Using the highly selective MEK
inhibitor, trametinib, we found that inhibiting acti-
vation of ERK1/2 abrogated dabuzalgron’s beneficial
effect on ATP synthesis after DOX.
Oxidative stress is central to the pathobiology of
DOX cardiotoxicity and arises in part from compro-
mised mitochondrial function (24). To assess further
the functional implications of these transcriptional
findings, we measured thiobarbituric acid reactive
substances (TBARS), in mouse heart tissue. TBARS, a
measure of lipid peroxidation, were more abundant in
the hearts of mice treated with DOX. Coadministration
of dabuzalgron normalized TBARS content (Figure 3E).
In summary, dabuzalgron protected against the
reduction in transcripts related to mitochondrial
function, preserved ATP content, and reduced
oxidative stress in the hearts of mice treated with
FIGURE 2 Dabuzalgron Protects Mice Against DOX Cardiotoxicity by Activating the a1A-AR
(A) WT mice and knockout mice lacking the a1A-AR (AKO) underwent baseline awake echocardiography, received either doxorubicin
(DOX) 20 mg/kg or vehicle control (VC) by intraperitoneal (IP) injection, then 7 days of treatment with either dabuzalgron 10 mg/kg or
water by gavage twice daily. On Day 7, the mice underwent awake echocardiography before sacrifice. All analyses included only mice
that survived to Day 7. (B) Fractional shortening, a measure of contractile function, with representative M-mode echocardiogram
images. Results for mice that survived to Day 7 were compared in indicated groups using the Student t test, assuming normal
distribution of values. (C) Day 7 heart sections stained with Masson Trichrome. Fibrosis (weighted average collagen content) was
quantified using Aperio ImageScope software. Results were compared across treatment conditions by analysis of variance. Abbreviations
as in Figure 1.
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Vehicle (12) 100% 27.3  0.6 27.8  0.6 17.2  0.1 126  3 0.45  0.01 7.3  0.2 7.1  1.2
Doxorubicin þ vehicle (14) 78% 28.1  0.7 25.1  1.2* 17.9  0.2 104  7* 0.41  0.01* 5.8  0.4* 8.2  0.3
Doxorubicin þ dabuzalgron (14) 86% 27.3  0.5 24.3  0.6* 17.6  0.1 97  5* 0.41  0.02* 5.5  0.3* 7.7  0.4
a1A-KO
Vehicle (3) 100% 26.7  0.9 26.7  0.9 17.0  0.0 118  7 0.44  0.02 6.9  0.4 5.2  0.3
Doxorubicin þ vehicle (3) 38% 29.9  0.7 26.8  1.2 17.5  0.3 101  9 0.42  0.02 5.8  0.3* 5.0  0.3
Doxorubicin þ dabuzalgron (4) 50% 29.3  0.6 26.4  1.2 17.4  0.1 101  5* 0.39  0.01* 5.6  0.2* 5.1  0.2
Values are mean  SEM. Anatomic data are included only for mice that survived 7 days. *p < 0.05 vs. genotype vehicle.
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45DOX. These beneficial effects may be mediated by
activation of ERK1/2 and up-regulation of PGC1a.
ERK1/2 ACTIVATION CONTRIBUTES TO THE
CARDIOPROTECTIVE EFFECTS OF DABUZALGRON.
NRVMs express the a1A and a1B subtypes, have been
used extensively to assess the effects of non-selective
a1-AR activation, and faithfully predict in vivo a1-AR
biology (25,26). To test the effect of an a1A agonist on
uninjured NRVMs, we administered various concen-
trations of dabuzalgron. After 15 min of treatment, we
blotted NRVM lysates for activation of ERK (Figure 4A),
a canonical downstream signaling partner of the a1A
that mediates the cytoprotective effects of a1A acti-
vation in vitro (13). Dabuzalgron increased ERK
phosphorylation in a dose-dependent fashion with
a half-maximal effective concentration (EC50) of
4.8  107 mol/l (Figure 4B). The pERK/ERK ratio
was increased roughly 1.5-fold after treatment with
dabuzalgron 10 mmol/l, an effect equivalent toTABLE 3 Echocardiographic Parameters After Doxorubicin Treatmen
HR LVIDd LVI
Wild type (n)
Doxorubicin þ vehicle (14)
Day 0 658  30 2.9  0.1 1.4 
Day 7 613  23 2.8  0.1 1.5 
Doxorubicin þ dabuzalgron (14)
Day 0 630  59 3.0  0.2 1.4 
Day 7 667  10* 2.8  0.1 1.3 
a1A-KO (n)
Doxorubicin þ vehicle (3)
Day 0 679  38 3.0  0.1 1.3 
Day 7 661  21 3.0  0.2 1.7 
Doxorubicin þ dabuzalgron (4)
Day 0 703  13 2.8  0.1 1.3 
Day 7 618  19 2.8  0.1 1.6 
Values are mean  SEM. Echocardiography was performed on unanesthetized mice. Data
versus doxorubicin þ vehicle.
FS ¼ fractional shortening (%); HR ¼ heart rate (beats/min); IVSd ¼ interventricula
LVIDd ¼ left ventricular internal diameter, diastole (mm); LVIDs ¼ left ventricular inter
ventricular systolic volume (ml); PWd ¼ posterior wall, diastole (mm).norepinephrine 1 mmol/l (in the presence of the
nonselective b-AR blocker, propranolol 1 mmol/l)
(Figure 4C).
We then tested the role of ERK activation in
dabuzalgron’s cardioprotective effects in vivo using
trametinib. Trametinib (1 mg/kg by gavage once
daily) almost completely eliminated ERK activation
(Figures 4D and 4E). DOX also reduced ERK activation,
consistent with previous reports (27). Treatment
with dabuzalgron partially mitigated that effect but
could not restore ERK activation after trametinib
(Figures 4D and 4E). Coadministration of trametinib
with DOX and dabuzalgron abrogated dabuzalgron’s
protective effect on contractile function (Figure 4F),
suggesting that a1A-mediated positive inotropy re-
quires ERK activation.
DABUZALGRON PROTECTS NRVMs FROM CELL DEATH
DUE TO DOX. Previous studies showed that adenoviral
infectionwith the a1A is cytoprotective in vitro, but thet With or Without Dabuzalgron 20 mg/kg/day
Ds FS LVd vol LVs vol IVSd PWd
0.1 54  2 34  4 5  1 0.9  0.0 0.8  0.0
0.1 46  2 31  3 7  2 0.9  0.0 0.8  0.0
0.1 50  3 36  6 5  1 0.9  0.1 0.9  0.0
0.0* 53  1* 31  2 5  0* 0.9  0.0 0.9  0.0
0.0 55  1 34  2 5  0 1.1  0.1 1.1  0.1
0.1 43  2 34  4 9  2 1.2  0.0 1.1  0.0
0.1 54  1 30  3 4  1 1.1  0.0 1.1  0.1
0.0 42  2 29  2 8  1 1.1  0.0 1.1  0.1
are included only for mice that survived to Day 7, n given in parentheses. *p < 0.05
r septal thickness, diastole (mm); LVd vol ¼ left ventricular diastolic volume (ml);
nal diameter, systole (mm); LVm ¼ left ventricular mass, calculated; LVs vol ¼ left
FIGURE 3 Dabuzalgron Augments Mitochondrial Transcript Expression and Function in Hearts From Mice Treated With DOX
Male mice were treated with either DOX 20 mg/kg or vehicle by IP injection followed by 7 days gavage with either dabuzalgron 10 mg/kg twice
daily, water, or trametinib (Trm) (1 mg/kg daily). Heart tissue was collected and immediately flash frozen on Day 7. (A) RNAseq was per-
formed using RNA from the hearts of 3 mice per group (PBS þ water; PBS þ dabuzalgron; DOX þ water; DOX þ dabuzalgron). Gene set
analysis was performed on DESeq2-derived statistics across these four categories. The results were highly enriched in gene sets involved in
mitochondrial processes, a selection of which is shown here. (B) RNA abundance for all sequenced cytochrome C oxidase subunits
(25 genes), mitochondrial complex I subunits (42 genes), and ATP synthase subunits (17 genes) was normalized by individual gene to vehicle
treatment, then aggregated by treatment group. (C) Quantitative reverse transcription polymerase chain reaction for peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1a) was performed on mouse heart tissue (n in individual bars) (D) ATP content was
measured in freshly harvested mouse heart tissue (total n in individual bars), then quantified relative to protein content. Results are
presented relative to vehicle treatment for 4 independent experiments. (E) Thiobarbituric acid reactive substances (TBARS) were assayed in
mouse myocardium. Abbreviations as in Figures 1 and 2.
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FIGURE 4 Dabuzalgron Activates ERK, A Canonical Signaling Partner of the a1A-AR
(A) NRVMs were pre-treated with the b-AR antagonist propranolol then exposed for 15 minutes to dabuzalgron. The non-selective a1-AR
agonist norepinephrine (NE) was a positive control. Lysates were blotted for total and phospho-ERK (pERK). (B) The EC50 was calculated
from 4 concentrations of Dabuzalgron across 5 separate experiments. (C) Summary of pERK/ERK for experiments using 5 different NRVM
isolations. The average pERK/ERK ratio ($2 individual wells) for each experiment was normalized to the pERK/ERK ratio for vehicle-treated
NRVMs. (D and E) Mice were treated with DOX, DOX and dabuzalgron, Trm, or DOX, dabuzalgron and Trm for 7 days. Heart lysates were
blotted for pERK and ERK. Results were compared using 1-way analysis of variance with Tukey post-test. (F) Mice underwent conscious
echocardiography after 7 days of treatment with Trm, DOX and Trm, or DOX, Trm, and dabuzalgron. EC50 ¼ half-maximal effective con-
centration; NRVM ¼ neonatal rat ventricular myocyte; other abbreviations as in Figures 1 to 3.
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FIGURE 5 In NRVMs, Dabuzalgron Protects Against Apoptotic and Necrotic Cell Death Due to DOX
NRVMs were treated for 4 h with doxorubicin 2mM in the presence and absence of dabuzalgron 10 mmol/l. Apoptosis was detected using
fluorescein isothiocyanate–labeled Annexin V, cell death was detected using propidium iodide (PI), and nuclei were labeled with Hoechst.
(A) Representative epifluorescence microscopy for each treatment condition. (B) Fluorescent intensity was analyzed using ImageJ 1.41
software (NIH, Bethesda, Maryland) for 3 independent experiments, using at least 2 wells per condition for each experiment. An average of
352 nuclei were counted in an average of 6 microscopic fields per experiment. Abbreviations as in Figures 1 to 4.
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48effects of selective a1A activation have not been tested
previously. To test the cytoprotective effects of an a1A
agonist, we treated NRVMs with DOX 2 mmol/l in the
presence and absence of dabuzalgron 10 mmol/l, then
assayed apoptosis and cell death using Annexin V-FLUOS and propidium iodide (Figure 5A). Four-hour
treatment with DOX increased apoptosis (Annexin V
staining), and necrotic cell death (costaining with
Annexin V and propidium iodide) (Figure 5B).
Concomitant treatment with dabuzalgron abrogated
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49these effects. Treatment with dabuzalgron in the
absence ofDOXdidnot changeAnnexinVor propidium
iodide staining when compared with untreated cells.
DABUZALGRON REGULATES ACTIVATORS OF
APOPTOSIS AND MITOCHONDRIAL MEMBRANE
POTENTIAL IN NRVMs. In light of our findings that
treatment with dabuzalgron preserved mitochondrial
function in vivo and protected against cell death
in vitro after DOX exposure, we sought to explore the
effect of dabuzalgron on aspects of mitochondrial
function in NRVMs. Maintenance of mitochondrial
membrane potential is essential to ATP generation, and
loss of membrane potential can contribute to apoptosis
by increasing cytochrome c release (28), leading to
activation of proapoptotic effectors. DOX interferes
with the cellular capacity to maintain mitochondrial
membrane potential and mitochondrial dysfunction
contributes significantly to DOX cardiotoxicity (24).
To test the effect of a1A activation on mitochon-
drial membrane potential, we treated NRVMs with
DOX 2 mmol/l for 4 h in the presence or absence of
dabuzalgron 10 mmol/l then stained with the mem-
brane permeant dye, JC-1. JC-1 exists as a green
fluorescent monomer at low mitochondrial mem-
brane potential and a red fluorescent aggregate at
high mitochondrial membrane potential. DOX led to a
profound loss of mitochondrial membrane potential
that was partially rescued by coadministration of
dabuzalgron (Figures 6A and 6B).
To examine the role of a1A-mediated mitochon-
drial protection on DOX-induced apoptosis, we
immunoblotted NRVM lysates for cytochrome c and
downstream apoptosis effectors. DOX increased cy-
tochrome c release and caused cleavage of caspases
and PARP, suggesting that mitochondrial damage
induced activation of the intrinsic apoptosis pathway,
consistent with previous characterizations of DOX
cytotoxicity (29). Coadministration of dabuzalgron
abrogated these changes (Figure 6C).
In summary, activation of the a1A-AR with dabuzal-
gron mitigated the detrimental effects of DOX on mito-
chondrial membrane potential and abrogated the
activation of important elements of the apoptotic
response to mitochondrial damage. These findings sug-
gest that preservation of mitochondrial function may
underlie the cytoprotective effects of a1A activation.
DISCUSSION
The central novel finding of this study is that the oral
selective a1A-AR agonist, dabuzalgron, is protective
against anthracycline-induced cardiotoxicity. Though
dabuzalgron has not been tested previously in animal
models of heart injury, it was well tolerated in 2 largerandomized clinical trials for treatment of urinary
incontinence. We found that its cardioprotective ef-
fect is mediated in part through preservation of
mitochondrial function, an adaptive mechanism that
has not been attributed previously to activation of
cardiac a1A-ARs.
a1-ARs are best known as vascular receptors, where
a1-AR activation promotes vasoconstriction. At high
doses, nonselective a1-AR agonists such as phenyl-
ephrine increase BP experimentally and clinically. In
this study, we found no effect on BP or HR in mice
treated with a range of dabuzalgron doses. We chose
to use 10 mg/kg for subsequent experiments because
Roche studied this dose in pigs and rabbits (10). Our
findings mirror the published human experience with
dabuzalgron as a treatment for urinary incontinence,
wherein administration of 1.5 mg by mouth twice
daily did not alter BP or HR (11).
Though cardiac a1-ARs are a minor AR subpopula-
tion relative to b1-ARs, they contribute to numerous
important processes in the heart (26). Subpressor doses
of nonselective a1-AR agonist also can cause cardiac
hypertrophy, indicating a direct and load-independent
effect on the heart (30). We found that activation of the
a1A did not cause myocardial hypertrophy, consistent
with the fact that heart size is normal in mice with
global and cardiac-specific a1A overexpression (4–6).
a1AKO mice on a congenic C57Bl6 background also
have normal heart size and BP (data not shown). Mice
lacking both myocardial a1 subtypes (a1ABKO) have
small hearts (31). Collectively, these findings suggest
the a1B subtype mediates cardiomyocyte hypertrophy
induced by non-selective a1-AR agonists.
We found that oral administration of a subpressor
dose of dabuzalgron protected WT mice against DOX
cardiotoxicity. This beneficial effect was absent in AKO
mice, indicating that dabuzalgron’s adaptive effects
result from on-target activation of the a1A. High mor-
tality and very poor contractile function in DOX-treated
AKO mice further reinforce the cardioprotective func-
tion of the a1A-AR. Though other labs have used
transgenic overexpression of the a1A to identify car-
dioprotective effects, ours is the first study to our
knowledge to demonstrate greater susceptibility to
cardiac injury in AKO mice. As such, we present evi-
dence supporting adaptive functions for cardiac a1A-
ARs using both novel pharmacological gain-of-function
and novel genetic loss-of-function approaches.
The function of a1-ARs in cardiomyocyte mito-
chondria has not been explored to any significant
extent previously. In our study, dabuzalgron protected
against DOX-induced apoptosis and necrosis in NRVMs
and decreased levels of intrinsic apoptotic effectors,
suggesting that this benefit may be associated with
FIGURE 6 In NRVMs, Dabuzalgron Regulates Activators of Apoptosis and Protects Mitochondrial Membrane Potential After
Treatment With DOX
NRVMs were treated for 4 h with doxorubicin 2 mmol/l in the presence and absence of dabuzalgron 10 mmol/l. (A and B) Mitochondrial
membrane potential was assessed using JC-1, and fluorescent intensity was quantified using a plate reader. Red indicates intact mitochondrial
membrane potential; green indicates compromised mitochondrial membrane potential. Representative images (A) and summary findings (B)
are presented. (C) NRVM lysates were blotted for selected regulators of apoptosis and mitochondrial cell death effectors. Representative
Western blots and summary findings from 3 independent experiments with at least 2 wells per condition in each experiment are shown.
Abbreviations as in Figures 1 to 4.
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51preservation of mitochondrial integrity and function.
Analysis of our RNAseq results showed rescue of
pathways associated with mitochondrial function and
metabolism after therapeutic a1A activation, a previ-
ously unrecognized mechanism for a1A activity.
Treatment with DOX diminished transcript abundance
within these pathways, whereas coadministration of
dabuzalgron restored expression of complex I, cyto-
chrome c oxidase, and ATP synthase genes. Treatment
with dabuzalgron abrogated the DOX-induced reduc-
tion in myocardial ATP levels, indicating functional
significance of the transcriptional changes. Though we
cannot exclude a contribution from other cell types to
these findings, they seem most likely to represent
changes in cardiomyocytes because the a1A is not
expressed on nonmyocytes in the heart (32).
We show that dabuzalgron activates ERK, a canon-
ical downstream signaling partner of the a1A in
NRVMs, and partially restores ERK activation in the
hearts of mice treated with DOX. Using the highly se-
lective MEK inhibitor, trametinib, we demonstrate
that ERK phosphorylation is necessary for dabuzal-
gron’s protective effects on inotropy and ATP synthe-
sis. ERK activation was found to be critical to
a1A-mediated cytoprotection in previous work using
adenoviral constructs in vitro (13), but our experiments
are the first to show ERK activation in vivo by an a1A
agonist. Interestingly, dabuzalgron-mediated car-
dioprotection does not require full restoration of ERK
activation to levels seen in uninjured heart. Given the
broad cellular effects of DOX, it is possible that DOX
impairs ERK activation through multiple pathways,
not all of which are modified by a1A activation. a1-ARs
can activate ERK through multiple pathways, both
PKC-dependent (33) and PKC-independent (34), sug-
gesting signaling resilience. Furthermore, a1A activa-
tion might mitigate the adverse effects of DOX on
abundance of activated ERK by targeting activated
ERK to caveolae, where its function is enhanced, as
shown previously in vitro (35,36).
STUDY LIMITATIONS. One potential limitation of our
study is the use of an acute DOX toxicity model. We
administered 20 mg/kg of DOX intraperitoneally, a
dose that allometrically scales to roughly 60 mg/m2 in
humans. Though this scaled dose is at the upper limit
of the typical range for treatment of breast cancer and
lymphoma, the observed mortality in our studies is
out of proportion to the insult to cardiac function,
suggesting that mice may suffer noncardiac toxicities
at this dose that are not fully representative of the
human response. The pathogenesis and signaling
associated with acute DOX cardiotoxicity likely are
distinct from chronic DOX cardiomyopathy, and the
contribution of oxidative stress in this model may bedisproportionately represented. Chronic cardiomy-
opathy is the most significant source of DOX-
associated cardiac morbidity; however, numerous
studies indicate that acute DOX cardiotoxicity is more
common than previously thought (11% [37] to 21%
[38]) and predicts poor outcomes. In one recent study,
32% of subjects had elevated troponin I (TnI) acutely
after DOX. Ejection fraction dropped measurably in
most subjects by 3 months and early þTnI predicted
durable reduction in ejection fraction (39). In a follow-
up study, the authors found that early institution of
evidence-based HF therapy protected against chronic
anthracycline cardiomyopathy (40). Collectively,
these findings suggest that acute DOX cardiotoxicity
may be a clinically meaningful and actionable entity.
We have proposed previously that a1-AR agonists
could be used to treat HF (25). Anthracycline-induced
cardiac dysfunction is not wholly representative of
the various causes of human HF, but there are some
commonalities. In particular, mitochondrial dysfunc-
tion and impaired cardiomyocyte energetics are central
to the pathobiology of HF regardless of etiology (41).
Unlike b-ARs, the abundance of a1A is maintained or
increased in failing human heart tissue (42,43). One
small study indicated a benefit from the use of the
nonselective a1-AR agonist midodrine in patients with
advanced HF (44). Long-term selective activation of
the a1A for treatment of HF has not been tested thera-
peutically, though the present results suggest that this
novel approach may have promise. Interestingly, long-
term systemic 2-fold overexpression of the a1A actually
is associatedwith prolonged lifespan, decreased cancer
incidence (45), and improved cognition (46).
CONCLUSIONS
Future mechanistic work will examine the role of the
a1A-AR in regulating mitochondrial function and
cellular energy production. We also plan to test se-
lective a1A-AR activation with dabuzalgron in other
mouse models of HF. These studies will help to
determine the therapeutic potential of repurposing
this well-tolerated oral a1A-AR agonist for the treat-
ment of HF.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
detrimental role of chronic catecholaminergic hyperstim-
ulation of cardiac b-ARs is a well-recognized aspect of HF
pathobiology and antagonizing those effects with b-
blockers is central to the treatment of HF. Cardiac a1-ARs
are a smaller population of receptors that also are acti-
vated endogenously by the catecholamines, norepineph-
rine and epinephrine. Emerging data indicate that a1-ARs
mediate adaptive, rather than toxic, effects in the heart.
Here we use dabuzalgron, an oral a1A-AR agonist, to
protect against DOX-induced cardiotoxicity and HF in
mice. Our findings reinforce previous cell and animal data
demonstrating cardioprotection through the a1A-AR, and
suggest that dabuzalgron might be used to treat other
forms of HF.
TRANSLATIONAL OUTLOOK: We chose to study
dabuzalgron because it has a published record of safety
and tolerability in previous clinical trials for treatment of
urinary incontinence. Hence, developing dabuzalgron as a
HF treatment would not require extensive preclinical
toxicological testing. Indeed, many of the medications
that currently are used to treat HF have been repurposed
from other indications. Confirmation of the therapeutic
potential of dabuzalgron will require demonstration of its
efficacy in other animal models of HF. Although dabu-
zalgron was well tolerated by hundreds of women with
urinary incontinence, its safety would need to be evalu-
ated in Phase 1 studies of patients with heart disease.
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